Monday, 13 April 2020

Mitochondrial Myopathies Market Competitors Analysis: Till 2023

Mitochondrial Myopathies Market 2019 Global Size, Share, Emerging Trends, Business Growth, Company Profile, Historical Analysis, Development Status and Opportunity Assessment by Forecast 2023

Market Synopsis of Global Mitochondrial Myopathies Market:
Market scenario:
The growing number of m mitochondrial myopathy invalids is likely to spur the global mitochondrial myopathies market growth over the forecast period. The major issue with mitochondrial myopathies is that, it is a genetic disorder and till today, has no proper cure. This, is observed to generate boundless scope for research. The strong support of governments, across the world, is encouraging researchers for undertaking numerous research and developmental projects to develop effective treatment for mitochondrial myopathies. Hence, this factor can cast a positive influence on the mitochondrial myopathies market growth. The availability of certain diagnostic aids for the mitochondrial myopathies and their precise results are also expected to amplify the market growth. The presence of reimbursement and medical insurance policies for rare genetic diseases like mitochondrial myopathies can rise the profit margins of the mitochondrial myopathies market.
However, the unavailability of specific treatment regime for mitochondrial myopathies and lack of cognisance of the availability of enhanced diagnostic solutions for detecting mitochondrial myopathies are certain factors, which can interfere the mitochondrial myopathies market expansion.
The Mitochondrial Myopathies is expected to reach $ 600 million by the end of 2023, this market is projected to growing at a CAGR of ~ 3.2 % during 2017-2023.
Top-Notch Key Players                                         
MRFR profiled eminent companies which are operating in the global mitochondrial myopathies market. They are; Khondrion BV, Reata Pharmaceuticals, Inc., GeneDx, Stealth BioTherapeutics, NeuroVive Pharmaceutical AB, Centogene AG, and Raptor Pharmaceutical Corp.
Segments:
Type, diagnostic tests, and therapies are segments, under which the global mitochondrial myopathies market has been studies.
Based on the type, the mitochondrial myopathies market has been segmented into Mitochondrial encephalomyopathy, Kearns-Sayre syndrome (KSS), Pearson syndrome, Mitochondrial DNA depletion syndrome (MDS), Leigh syndrome, Myoclonus epilepsy with ragged red fibers (MERRF), Progressive external ophthalmoplegia (PEO), Mitochondrial neuro-gastrointestinal encephalomyopathy (MNGIE), and Neuropathy, ataxia and retinitis pigmentosa (NARP).
Based on therapies, the mitochondrial myopathies market has been segmented into vitamins, coenzymes and antioxidants, supportive, dietary, and other.
Based on diagnostic aids, the mitochondrial myopathies market has been segmented into genetic test, muscle biopsy, and blood enzyme test.
Regional analysis
Based on the region, the global mitochondrial myopathies market has been studied across North America, Asia Pacific, Europe, the Middle East Asia and Africa.
The US in North America, is to hold the largest share of the regional market, while, North America dominates the global mitochondrial myopathies market. The strong economy empowering North America is likely to bolster the market growth over the assessment period. Furthermore, the increasing number of screening tests is also expected to escalate the US market growth. To illustrate, in the U.S., the new-born screening is performed on a infant, despite, its parent’s health insurance status or ability to bear medical expenses or charged minimum for the testing. The expansion of mitochondrial myopathies patient pool and surge in the government support for research and development undertakings are other factors, which can drive up the American mitochondrial myopathies market. Continuous technical upgradation backing medical advancements are identified to spur the South American mitochondrial myopathies market. The existence of private health insurance plans like Medicaid and the Children's Health Insurance Program (CHIP) and likely to cast a positive impact on the regional mitochondrial myopathies market expansion.
The Asia Pacific region is to exhibit a fast-paced growth for the mitochondrial myopathies market. Emerging economies like India and China are likely to witness a considerable market growth due to the rising need to meet the existing medical backlogs.  However, owing to political loopholes and fragile economic condition in the Africa, the market can experience a stagnancy in the growth over the review period. But, the mitochondrial myopathies market is expected to be led by the Gulf nations, particularly Saudi Arabia and UAE.
Posted by at No comments:

Esophageal Cancer Market Value Chain, Factor Analysis, Region And Forecasts Till 2023

Esophageal Cancer Market Scenario:
Cancer is one of the leading causes of death worldwide and is expected to witness the expansion of patient population in the years to come. One of the types of cancer that affect the food pipe connecting the mouth and stomach is the esophageal cancer which is majorly prevalent among the older adults belonging to 55 years and above age group. Market Research Future (MRFR) has found out that the global esophageal cancer treatment market is projected to grow at a compound annual rate of 8.7% during the forecast period 2017 to 2023. It is underlined in the report that the market is anticipated to scale a decent valuation of USD 1000.1 Mn towards the close of 2023.
The rising burden of cancer has paved the way for innovation in the market. It is one of the prime areas of research in the medical field. With the increasing number of drug patent applications in conjunction with the rising count of clinical trials, the esophageal cancer market size is expected to witness a boom over the next couple of years. Key players are anticipated to exponentially invest in the development of more effective treatments which is forecasted to aid the proliferation of the esophageal market in the foreseeable future.
Addiction to tobacco, betel nuts, etc. is the key factor responsible for triggering esophageal cancer. Increasing shift towards a sedentary lifestyle has led to an increase in addiction problems among the masses. This, in turn, is expected to catalyze the growth of patient population. The future trajectory of the esophageal market is likely to remain highly lucrative over the next couple of years.
People are getting increasingly aware of the availability of treatments which is poised to aid market expansion. The support extended by governments in conjunction with the early detection of the disease has unleashed massive opportunities for the market players. It is anticipated to augment the esophageal cancer market in the long run.
Segmentation:
The global esophageal cancer market is segmented on the basis of type. Based on the type, the market has been segmented as esophageal squamous-cell carcinoma, esophageal adenocarcinoma and others. Based on the phases, the market has been segmented as phase I, phases II and phases III. Based on the treatment, the market has been segmented as surgery, chemotherapy and radiotherapy and other.
Intended Audience
  • Global Esophageal cancer solutions providers, manufacturers & suppliers
  • Research and development (R&D) companies
  • Market research and consulting service providers
  • Academic institutes and universities
Regional Analysis
The market of esophageal cancer is much higher in the Americas region attribute to high rate of tobacco, alcohol, very hot drinks, poor diet, and chewing betel nut. According to report published by American Cancer Society, in 2018, it is estimated that around 17,290 new cases of esophageal cancer diagnosed in Americas which include 13,480 of men and 3,810 of women and around 15,850 will be die. Additionally, In the United States, up to 200,000 people die each year from smoking-related illnesses that leads to incidence of esophageal cancer in this region. The government have more focus towards research and development for introducing the best treatment for their population.
Asia Pacific region are considering the growing market, owing to presence of huge population suffering with esophageal cancer. Whereas country like India and china are considering fastest growing region due to the high rate of tobacco and alcohol consumption which leads the incidence of esophageal cancer, additionally they are open to adopt new technology, and best treatment option from developed countries in order to improve the quality of life for their citizen. Whereas, the Middle East and Africa have low market due to his incapability of investment, Moreover, developing countries are still focusing on new drugs for the treatment of esophageal cancer, this gap between the developed and developing countries will present significant growth opportunity for the esophageal cancer market players in the coming years.
Europe is also consider huge market for esophageal cancer players, owing to present of huge population affected with disease. According to Cancer Research U.K, in 2014, esophageal cancer holds 2 percent of total cancer cases in United Kingdom. Government are more focusing to educate their public in order to minimize the patient’s population by educating them about the side effect of tobacco, alcohol etc.
Key players of Global Esophageal cancer Market:
  • Amgen
  • Eli Lilly and Company,
  • Hoffmann-La Roche,
  • Bristol-Myers Squibb Company,
  • Boehringer Ingelheim GmbH,
  • Bristol-Myers Squibb,
  • GlaxoSmithKline Plc.,
  • Novartis AG,
  • Johnson & Johnson,
  • Gilead Sciences,
  • Merck & Co.
Posted by at No comments:
Labels:

Africa Malaria Diagnosis & Treatment Market Trend, Industry Overview, Competitive Analysis And Foreseen By 2023

Africa Malaria Diagnosis & Treatment Market Information, by product (diagnostic, therapeutics, medical care and nutrition and wellness) by application (diagnosis and intervention, drug development and usage, cancer genomics and others), by End users (hospitals, molecular diagnostic laboratories and testing centers, academic institutes, bio and health informatics companies and others)- Forecast to 2023 
Market Synopsis of Africa Malaria Diagnosis & Treatment Market:
Malaria is an infectious disease caused by parasitic protozoa of the Plasmodium type. The symptoms include fever, fatigue, vomiting, and severe headaches and may lead to seizures, coma, or even death if untreated. Malaria is primarily a disease of the tropical and subtropical regions. The carrier of malaria is the female anopheles mosquito and hence there is a seasonal variation in the cases of malaria. Most cases of malaria are caused by P. falciparum because other types of plasmodium such as P. vivax, P. ovale, and P. malariae generally cause a milder form of malaria.
According to World Health Organization (WHO), the global incidence of malaria between 2010 and 2015, fell by 21% and the malaria mortality fell by 29%. However the African region carries a disproportionately high share of the global malaria burden and accounted for 90% of malaria cases and 92% of malaria deaths worldwide and sub-Saharan Africa accounted for 76% of malaria cases and 75% deaths globally.
Thus, unmet medical needs is the single most important driver of malaria. Other important market drivers are the hot and humid climatic conditions of certain parts of Africa, presence of population groups at higher risk of contracting malaria such as infants, children under 5 years of age, patients with low immunity such as those with HIV/AIDS, mobile populations and travelers.
The growth of government programs against malaria and the support given by international bodies such as WHO is also a market driver. The market barriers include high cost of imported malaria diagnostic kits, low penetration of healthcare in Africa, low per capita income, low number of healthcare professionals in Africa etc. The political causes include massive corruption, low political power of citizens especially in nondemocratic nations, civil war in regions such as Malawi etc.
Taking all factors into consideration, we expect the Africa malaria  diagnosis market to reach around $ 2418.92 million from $ 550 million in 2017, by the end of the forecast period at a CAGR of ~ 28.0 %. While the malaria treatment market will grow by a CAGR of 8.1% to reach around $ 7180.7 million from $ 4500.0 million in 2016.

Study Objectives for Africa Malaria Diagnosis & Treatment Market:
  • To provide detail analysis of the market structure along with forecast for the next 6 years of the various segments and sub-segments of the Africa malaria diagnosis & treatment market
  • To provide insights about factors affecting the market growth
  • To analyze the market based on various factors - price analysis, supply chain analysis, porters five force analysis etc.
  • To provide historical and forecast revenue of the market segments and sub-segments for Africa malaria diagnosis & treatment market
  • To provide country level analysis of the market with respect to the current market size and future prospective
  • To provide country level analysis of the market for segments by product type, by technique, malarial parasite and other sub segments.
  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments.
Intended Audience
  • Malaria Diagnostics Manufacturers and Suppliers
  • Medical Drugs Manufacturers and Suppliers
  • Private Research Laboratories
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Government Research Laboratories
  • Contract Manufacturing Organizations

Key Players for Africa Malaria Diagnosis & Treatment Market:
Some of the key players in this market are: Alere Inc., Access Bio Inc., Premier Medical Corporation, Beckman Coulter/Danaher, bioMerieux, Novartis Diagnostics, Siemens Healthcare, Bio-Rad Laboratories, Cipla Inc., Ipca Laboratories Ltd., Uni-Med India, Pfizer Inc., Sun Pharmaceutical Industries Ltd., Sanofi among others.

Segments:
Africa Malaria Diagnosis & Treatment Market has been segmented on the basis of technique which comprises rapid diagnostic tests (RDT’S), molecular diagnostics and microscopy. On the basis of malarial parasite; market is segmented into plasmodium falciparum, plasmodium vivax, plasmodium malariae and plasmodium ovale.

Regional Analysis of Africa Malaria Diagnosis & Treatment Market:
The healthcare sector of Africa is divided between private and state. The public healthcare expenditure accounts for approximately 48 % of total health expenditure in 2014 with variation in different countries. Local manufacturing represents a poor outlook which is limited to consumables and ordinary articles and there are a handful of high tech devices manufacturers. Africa is extremely dependent on imports for medical devices and imports account for approximately 90 % of total market for medical devices and Chinese medical device suppliers dominate the scenario. Among the regions of Africa, South Africa and Egypt account for 40 % of market. Other important nations are Nigeria, Morocco and Algeria. Collaboration with large global companies and technical transfer will remain the key strategy for developing the regional African market as can be seen by the example of China.

The report of Africa Malaria Diagnosis & Treatment Market of Market Research Future comprises extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions
Posted by at No comments:

U.S. Personalized Medicine Market Size Estimation By Top Manufacturer, Latest Trends And Global Industry Forecast 2019 To 2023

Market Highlights
The U.S. Personalized Medicine market analysis by MRFR has been evaluated as average growing market and expected that the market will reach high growth figures in coming years. A factsheet published by the WHO states that about 17.5 million people die due to cancer and other diseases every year, which is about 31% of the deaths across the globe. These alarming statistics are the obvious reason for growth of the U.S. Personalized Medicine market. Major factors driving the growth of this market include growing occurrence of autoimmune diseases during the forecast period and various other disease. Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics are more specific and effective thereby giving pharma/biotech companies an important advantage to recuperate R&D costs. Personalized medicine reduces the frequency of adverse drug reactions and therefore has a dramatic impact on health economics. Developmental and diagnostic companies benefit from lower discovery and commercialization costs and more specific market subtypes.
Test the market data and market information presented through more than 30 market data tables and figures spread over 60 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “U.S. Personalized Medicine market Research Report –Global Forecast to 2023.
U.S. Personalized Medicine market Players:
The major participants of this market are: Laboratory Corporation of America, Quest Diagnostics, Abbott, Becton Dickinson & Co., Siemens Healthcare Diagnostics Inc., GE Healthcare, Pfizer Inc., Sanofi, CardioDx Inc., Asuragen Inc. and Bristol-Myers Squibb.
Segmentation:
The U.S. Personalized Medicine Market is segmented on the basis of product, application and end users. Based on the product, the market has been segmented as diagnostic, therapeutics, medical care and nutrition and wellness and others. Diagnostic and therapeutic commands the maximum market share of U.S market and is expected to reach high growth figures in the coming future Based on application, the market has been segmented into diagnosis and intervention, drug development and usage, cancer genomics and others. Further on the basis of end users the market has been segmented as hospitals, molecular diagnostic laboratories and testing centers, academic institutes, bio and health informatics companies and others. Hospitals commands the largest market share followed by molecular centers due to increasing usage in these facilities of these medicines.
Regional analysis
U.S. accounts for the maximum market share of the personalized medicine market and the market is expected to increase continuously in coming years. This can be attributed to increasing pool of cancer patients along with high healthcare per capita expenditure. Advancing technologies within the liquid biopsy or cancer market is also driving the market and will see strategic growth over the next five years. The two segments of the liquid biopsy market are tumor cell enrichment products and tumor cell detection technologies which are expected to command the maximum market share.
The report for U.S. Personalized Medicine Market by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
Posted by at No comments:

India CRO Market 2019 - Shares, Revenue, Analysis And Forecasts Till 2023

India CRO Market Information, by Services Type (Clinical trials, Product Development, Process Development, Post-Marketing Surveillance, Quality Monitoring and Others); by Therapeutic Application (Oncology, Cardiovascular, Neurology, Nephrology and Urology, and Others) and by End Users (Pharmaceutical/biopharmaceutical Companies, Medical devices Companies and Academic Institutes) - Forecast till 2023
Market Synopsis of India CRO Market:
A Contract Research Organization (CRO) offers outsourced services to support R&D functions for pharmaceutical, biotechnology, and health companies. The services may be clinical research, product development such as drug development or process development such as bio analytical assay development. A CRO may also provide management services such as clinical trials management, and pharmacovigilance.
According to the analysis offered by Market Research Future (MRFR), the India CRO market has been presumed to flourish at a CAGR of 12.0% during the forecast period with overview of top cro companies in India.
The two important factors that are making India a favorable market for CRO include India’s acceptance of international guidelines and intellectual property rights. Other factors include the availability of the largest pool of patients and large hospitals, educated and accessible human resource (HR), low operational cost due to cheap HR, and lastly the presence of diverse types of climatic conditions that allow stability studies to be performed with ease in one destination. Some legal factors that favor the growth of India CRO market are efforts by the regulatory authorities such as Department of Biotechnology (DBT), Director Controller General of India (DCGI), Directorate General of Foreign Trade (DGFT), and Indian Council of Medical Research (ICMR).
The market constraints that can hamper the growth of India CRO market include growing concern for security especially data security and patient security and lack of collaboration between universities and industry etc. Sometimes, some unethical Indian CROs make dishonest comprises which creates trust issues among potential clients for CROs and hurts the market.
Segments:
India CRO market has been segmented on the basis of service types which comprises clinical trials, product development, process development, post-marketing surveillance, quality monitoring and others. On the basis of therapeutic application; market is segmented into oncology, cardiovascular, neurology, nephrology and urology, and others. On the basis of end users; market is segmented into pharmaceutical/biopharmaceutical companies, medical devices companies and academic institutes.
Regional Analysis of India CRO Market:
The western and southern regions of India hold a strong position in the CRO market due to their better infrastructure, education and salubrious climate. However the northern regions have started growing and catching up due to larger and more diverse genetic pool and the concentration of regulatory bodies in northern India. The faster growth of hospitals in northern India is favoring the CRO market and has led to this shift. The growth of diseases needing specialized care and treatments such as cancer is booming the CRO market of this segment at a faster pace than other segments.
India is emerging as a top destination for contract research organizations for the following reasons
  • India’s acceptance of International guidelines and intellectual property rights
  • Presence of diverse types of climatic conditions thus allowing stability studies to be performed with ease in one destination
  • Educated and accessible human resource in India
  • Presence of diverse ethnic pool thus enabling diverse sample for clinical trials
  • Low operational cost due to cheap human resource
  • Availability of largest pool of patients and large hospitals

Indian CRO Market - Competitive Landscape
The India CRO market is dominated by multinational CROs, followed by India CROs, multinational pharmaceutical companies, and Indian pharmaceutical companies. Among these, the Indian pharmaceutical companies are mainly engaged in conducting local trials.
In March 2018, The world's largest healthcare information provider and contract medical research, IQVIA, has recently stated that it is preparing to initiate outright buyouts to investments in start-ups for technologies that based on artificial intelligence and data analytics, while also considering those related to the healthcare sector as it converts into a "Human Data Science Company". Further, the company also stated that the investments in the future will be more directed towards development in the Asia Pacific region that includes China, India, Japan and South Korea where the company forecasts increasing demand for its services in the coming years.
In March 2018, Syngene International has entered into a multiyear R&D agreement with GlaxoSmithKline plc. The companies with this collaboration are focus to accelerate the discovery of new drug candidates using Syngene discovery services platforms.
Posted by at No comments:
Labels:

Global Carcinoid Syndrome Management Market Expected Tremendous Growth Till 2022

Market Research Future published a half cooked  research report on “Global Carcinoid Syndrome Management research report forecast to 2022” Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022.
Novartis International AG (Switzerland), Pharmascience Inc. (Canada), Omega Laboratories Ltd. (Canada), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (USA), Ipsen Biopharmaceuticals, Inc.(US), Sirtex Medical Limited (Australia) , BTG International Ltd. (UK), Wockhardt Ltd. , and  Sun Pharmaceutical Industries Limited (India), and others are some of the prominent players at the forefront of competition in the Global Carcinoid Syndrome Management and are profiled in MRFR Analysis. 
Global Carcinoid Syndrome Management - overview
The Global Carcinoid Syndrome Management is growing with the sound pace. According to a recent study report published by the Market Research Future, the Global Carcinoid Syndrome Management is booming and expected to gain prominence over the forecast period and is projected to grow a sound pace. The market is projected to demonstrate a sound growth by 2022, surpassing its previous growth records in terms of value with a sound CAGR during the anticipated period (2017-2022).
Carcinoid syndrome includes the signs and symptoms of flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are settled secondary to carcinoid tumor. Palliative and supportive care is often required for the management or treatment of carcinoid syndrome. Drug therapy and surgical removal of carcinoid tumor are the major management procedures for carcinoid syndrome. Increasing incidence of hormonal disorders, and growing smoking habits are the major drivers for the market growth. However, no availability of drugs approved to manage carcinoid syndrome may restrain the market growth during the forecast period.
Global Carcinoid Syndrome Management - competitive analysis
Characterized by the presence of several well-established and small players, the global market of carcinoid syndrome management appears to be highly competitive and fragmented. International players are increasingly expanding their footprint in the developing economy, making it difficult for regional vendors to compete with them, especially in terms of features such as product differentiation, product portfolios, quality, and pricing.  The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The intense competition prevalent in the market dictates the consolidation among marketers.
Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.
In November-2016, Novartis acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammatory disorders. Novartis exercised its right to acquire Selexys following receipt of results of the SUSTAIN study, a Phase II trial evaluating the use of SelG1, an anti-P-selectin antibody, in the reduction of vaso-occlusive pain crises in patients with sickle cell disease (SCD).
In August-2016, Teva Pharmaceutical Industries Ltd. and Allergan plc. Announced that Teva Pharmaceutical Industries Ltd. completed the acquisition of Allergan’s generics business. This strategic acquisition brought together two leading generics businesses with complementary strengths, R&D capabilities, product pipelines and portfolios, geographical footprints, operational networks and cultures.
In January-2017, Ipsen entered into a definitive agreement and acquire global oncology assets from Merrimack Pharmaceuticals, including its key marketed product ONIVYDE for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy, in combination with fluorouracil and leucovorin. Under the terms of the agreement, Ipsen gained exclusive commercialization rights for the current and potential future ONIVYDE indications in the U.S., as well as the current licensing agreements with Shire for commercialization rights ex-U.S. and PharmaEngine for Taiwan.
Global Carcinoid Syndrome Management - regional analysis
The Global Carcinoid Syndrome Management is segmented on the basis of regions, into North America, Europe, Asia-Pacific, and Middle East & Africa. America accounts for the largest market share of the Global Carcinoid Syndrome Management by region in 2016. High per capita healthcare expenditures followed by increasing awareness of the diseases and presence of the developed healthcare sector are the major drivers for the market growth during the forecast period. Followed by the North America, Europe holds the second largest market. Asia pacific is the fastest growing region. However, the Middle East and Africa region holds the least share of the global market, especially due to the presence of the poor economies within the Asia Pacific region. In the Middle East & African region, the Middle East holds the largest market share.
Posted by at No comments:

Sunday, 12 April 2020

Meningococcal Vaccines Market Global Research Report 2020 Analysis & Forecast to 2025

Market Highlights
According to MRFR analysis, Meningococcal Vaccines Market has a demand for USD 172 Million doses in 2019. Further, the global estimated supply in 2019 is expected to be 203 Million doses.
Despite broad and effective commitment from the global health community in meningitis A (MENA) vaccination in the meningitis belt, low manufacturing capacity and high prices across other meningococcal vaccine types have hindered access to these vaccines over the past several years. A more in-depth knowledge will benefit addressing these long-standing access issues and the development of the WHO global roadmap for overcoming meningitis by 2030. This is expected to set goals for disease control and vaccination for meningococcal meningitis on a global level.
Regional Analysis
Need for meningococcal vaccines is characterized by significant use outside of routine immunization: subnational use, immunization of special risk groups such as military personnel or travelers, private market use, or recommended but not-reimbursed immunization. In 2019, in addition to the 39 mostly HIC and meningitis belt countries that use meningococcal vaccines in national immunization programs NIPs, 27 countries use meningococcal vaccines only for special risk groups. National routine uses in 2019 accounts for approximately 100 million doses across all countries except for China.
However, other countries in the African and Eastern Mediterranean region have indicated interest in introducing a multivalent, conjugate vaccine into routine National Immunization Program Schedule, but have strived to access these vaccines due to the high price and limited availability.
Further, in 2018, 3.2 million doses were available in the Global stock, compared with 5 million doses that professionals forecast will be needed each year in the future, with more C- and W-containing vaccines needed to focus on the rising incidence of those serogroup globally.
Overall, demand for MenACWY conjugate is expected to increase over the short- and mid-term, as HICs and MICs show a growing inclination for immunization strategies targeting multiple serogroups and as Hajj pilgrims increasingly use MenACWY conjugate due to withdrawal of polysaccharide products.
Segmentation
The Global Meningococcal Vaccines Market has been segmented based on treatment type and end-user. The market, based on treatment type, has been divided into the meningococcal conjugate vaccine, polysaccharide, and subcapsular vaccine. In terms of end-user, the global meningococcal vaccines market has been segmented into hospitals & clinics, research & academic institutes, and others.
Key Players
Some of the key players in the Global Meningococcal Vaccines Market are Baxter International, Pfizer Inc., Novartis Pharmaceuticals Canada Inc, Sanofi S.A., JN-International Medical Corporation, Biomed Pvt. Ltd., Serum Institute of India Ltd., and GlaxoSmithKline among others.
Posted by at No comments:
Subscribe to: Posts (Atom)